Released Mar 23, 2023, before the open
10-K filed Mar 23, 2023, 82 days after period end · 0001785530-23-000009
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$11.93M-$11.93M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$13,179,000N/M
Operating Cash Flowderived-$11,870,000N/M
Free Cash Flowderived-$12,388,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Net Income | -$11.93M | -$17.87M | -$7.40M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR